Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA seeks more COI (conflict of interest) information from advisory panellists

This article was originally published in Clinica

Executive Summary

Experts who participate on US FDA product specific advisory panels are to be asked to provide more detailed information about their potential financial conflicts than they have in the past. Under a new conflict of interest (COI) policy, experts must categorise the size of their stock holdings, their consulting fees, their contracts and grants and their teaching speaking or writing fees. The disclosures will identify whether the interest is related to the sponsor or competitor that markets a competing product and whether the expert worked on the competing product or not.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT064584

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel